Abazyme to Present SLiCE™ Poster at PEGS May 7th, 2014 in Boston

CAMBRIDGE, Mass. - April 23, 2014 - PRLog -- Abazyme announced today that Chief Scientific Officer Dr. James R. Dasch, PhD, will present a case study of the use of its new cloning platform: SLiCE™. The poster entitled Splicing with SLiCE™: Assembly of IgG and ScFv Vectors for Recombinant Antibody Expression will be presented at the 10th Annual PEGS Summit in Boston, MA. Dr. Dasch will be presenting the poster on May 7^th-8^th as part of the Optimizing Protein Expression track at PEGS.

Abazyme, a recombinant antibody service provider, has focused on the cloning of hybridoma-based antibodies into stable expression vectors for its clients. To enable the ability to do this with greater efficiency than existing seamless cloning reagents, Abazyme has evaluated the use of SLiCE. Abazyme's wholly owned subsidiary, Abazyme Molecular LLC, has secured an exclusive license to the SLiCE technology and is now making this exciting new reagent available to the research marketplace. SLiCE allows for seamless cloning of DNA fragments with 20 to 50 base pair overlaps. No specialized vectors or restriction enzymes are required to achieve high cloning efficiency, which is 30 to 50 times more efficient than existing technologies.

During the development of SLiCE as a product for research use, scientists at Abazyme Molecular routinely recombine five PCR pieces comprising the entire pUC vector using 20 base pair overlaps, in a single SLiCE reaction.  After SLiCE treatment, greater than 700,000 transformants per microgram vector DNA are obtained. The use of SLiCE to construct IgG expression vectors from PCR amplified variable (V) region fragments featuring 20 base pair overlaps with a linearized mammalian expression vector, is now possible for Abazyme. The separate heavy-chain and light-chain vectors are transfected into HEK293 cells for expression. The SLiCE reaction is both rapid and easy and yields > 10⁶ colonies per µg of DNA. ScFv have also been assembled into E. coli expression vectors with SLiCE. The fidelity of the construction is 100% accurate via sequencing of the construct and functional assays for the resulting recombinant IgG and scFv. Even higher efficiencies can be obtained by combining SLiCE with competent cells with transformation efficiencies of >10⁹ colonies per µg.

“I am very pleased to launch this product to the molecular biology marketplace. It has enabled Abazyme to achieve much higher success at cloning than with previously used reagents” says Dr. Dasch. PEGS attendees are encouraged to view the Abazyme poster, Dr. Dasch will be available for questions and further information.

For further information on Abazyme, Abazyme Molecular or to order SLiCE™, please call 617-252-8243 or email us at slice@abazyme.com.


The original SLiCE publication can be found: http://nar.oxfordjournals.org/content/40/8/e55.long

About Us

Located in Cambridge, Massachusetts, Abazyme was created out of the understanding that one of the keys to successful life science research is the availability of excellent reagents and tools. Our clients range from small start-ups to major pharmaceutical companies. They all look to partner with Abazyme because of our proven technical track record and our willingness to serve as true research partners. We are researchers, so we "get" researchers. We've walked in their shoes and we understand that success comes from the performance of every step along the way. From synthetic biology, targeted drug discovery, diagnostic and therapeutic development, we aspire to provide services and products that solve problems.

In 2014, Abazyme created its subsidiary, Abazyme Molecular. Abazyme Molecular has launched its first commercial product: SLiCE™ cloning platform. In the future, Abazyme Molecular will be bringing innovative molecular cloning tools to the marketplace.

To learn more about PEGS 2014 and registration options, please visit www.pegssummit.com